Abstract

Sepsis and multiple organ dysfunctions due to cytokine storm are the leading cause of chronic kidney disease (CKD) worsened due to acute kidney injury (AKI). CytoSorb® therapy, a new hemoadsorption technology could be an alternative therapy to be used as an adjuvant in the hyper-cytokinemic state in patients with CKD. This is a case report of a 37-year-old male patient with CKD secondary to biopsy-proven chronic tubulointerstitial nephritis (CTIN) on conservative treatment. He was admitted to the emergency care department with complaints of dyspnea for the last 20 days and decreased urine output and constipation for the last 3 days. His dysregulated kidney and respiratory functions, deranged acid-base balance, and presence of elevated inflammatory markers were indicative of sepsis and cytokine storm. CytoSorb® therapy improved the outcomes remarkably for the patient. By the end of the treatment, serum lactate improved by 75.5% and urine output was improved by 167%. Mechanical ventilation was continued for six days, and regular dialysis was performed throughout the treatment. On Day 10, the patient’s condition had considerably stabilized. On Day 13, the patient was discharged in a hemodynamically stable condition. CytoSorb® device is a safe and effective treatment and can be used as an adjuvant therapy to stabilize critically ill CKD patients.